stockportfolio.pro
Quest Diagnostics Incorporated P/E Ratio 2007–2025
Quest Diagnostics Incorporated (DGX) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -0.7%/yr over 18 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 19.66 | +3.0% |
| FY 2024 | 19.08 | +8.9% |
| FY 2023 | 17.53 | -4.3% |
| FY 2022 | 18.31 | +79.9% |
| FY 2021 | 10.18 | -0.4% |
| FY 2020 | 10.23 | -31.6% |
| FY 2019 | 14.94 | +10.5% |
| FY 2018 | 13.53 | -10.4% |
| FY 2017 | 15.10 | -10.5% |
| FY 2016 | 16.87 | +42.4% |
| FY 2015 | 11.84 | -15.2% |
| FY 2014 | 13.97 | +86.2% |
| FY 2013 | 7.50 | -41.4% |
| FY 2012 | 12.81 | -14.3% |
| FY 2011 | 14.96 | +50.3% |
| FY 2010 | 9.95 | -14.0% |
| FY 2009 | 11.56 | -10.3% |
| FY 2008 | 12.90 | -41.8% |
| FY 2007 | 22.18 | — |
Source: Quest Diagnostics Incorporated SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Quest Diagnostics Incorporated
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeQuest Diagnostics Incorporated — frequently asked questions
What is Quest Diagnostics Incorporated's price-to-earnings ratio?
Quest Diagnostics Incorporated (DGX) reported price-to-earnings ratio of 19.66 for fiscal year 2025, per its SEC filings.
How has Quest Diagnostics Incorporated's price-to-earnings ratio changed over time?
Between fiscal 2007 and 2025, DGX's price-to-earnings ratio declined at roughly 0.7% per year (compound annual rate), from 22.18 to 19.66.
Where does this data come from?
Figures are computed from Quest Diagnostics Incorporated's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.